Eli Lilly: plans to submit two migraine drug applications
(CercleFinance.com) - Eli Lilly plans to submit a new drug application to the US Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine, the US drugmaker said in a statement on Wednesday.
Lilly also said that it plans to submit a supplemental biologics license application (sBLA) to the FDA for another compound - Emgality - for the preventive treatment of episodic cluster headache by the end of the year.
The company said that the FDA has granted breakthrough therapy designation to Emgality for episodic cluster headache.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Lilly also said that it plans to submit a supplemental biologics license application (sBLA) to the FDA for another compound - Emgality - for the preventive treatment of episodic cluster headache by the end of the year.
The company said that the FDA has granted breakthrough therapy designation to Emgality for episodic cluster headache.
Copyright (c) 2018 CercleFinance.com. All rights reserved.